Source disclosure: February 13, 2026
Medrx Co.,Ltd. [4586.T]
TOKYO, Feb 13 (Pulse News Wire) – Medrx CO.,LTD. (4586.T) announced changes to the expenditure schedules for funds raised through equity warrants issued in its 25th and 32nd tranches.
For the 25th tranche, the company delayed the start of clinical Phase II trials for MRX-4TZT, a spastic paralysis treatment drug, to December 24, 2025. As a result, expenses originally planned for the fiscal year ending December 2025 will now be deferred until the fiscal year ending December 2026. Specifically, the development costs for a new Paipurain Soushutsu drug remain unchanged at ¥210 million for April to December 2023, while the clinical trial costs for MRX-4TZT have been extended to December 2026, totaling ¥817 million.
In addition, for the 32nd tranche, due to further delays in initiating the MRX-4TZT clinical Phase II trials, which began on December 24, 2025, the company has decided to extend the spending schedule beyond December 2026. Expenses related to the clinical trial preparation costs for MRX-4TZT have been adjusted to run until December 2026, amounting to ¥140 million. Other expenditures such as marketing preparations and maintenance fees for MRX-5LBT ("Bondlido") and research and development costs remain largely unchanged but have seen minor adjustments in their respective timelines.
These modifications reflect the company's ongoing commitment to managing its resources effectively amidst evolving project timelines.
AI-translated content. 🟢 Confidence: High See terms • Original filing